Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Total Current Liabilities (2019 - 2025)

Vivos Therapeutics' Total Current Liabilities history spans 7 years, with the latest figure at $18.1 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $18.1 million for Q4 2025, up 263.12% from a year ago — trailing twelve months through Dec 2025 was $18.1 million (up 263.12% YoY), and the annual figure for FY2025 was $18.1 million, up 263.12%.
  • Total Current Liabilities for Q4 2025 was $18.1 million at Vivos Therapeutics, up from $7.4 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $18.1 million in Q4 2025 to a low of $4.7 million in Q1 2025.
  • The 5-year median for Total Current Liabilities is $7.2 million (2023), against an average of $7.5 million.
  • Peak annual rise in Total Current Liabilities hit 263.12% in 2025, while the deepest fall reached 41.75% in 2025.
  • Year by year, Total Current Liabilities stood at $7.5 million in 2021, then fell by 9.27% to $6.8 million in 2022, then increased by 6.99% to $7.3 million in 2023, then tumbled by 31.71% to $5.0 million in 2024, then skyrocketed by 263.12% to $18.1 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $18.1 million, $7.4 million, and $6.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.